key: cord-0945245-qezmdxil
authors: Teo, Kelvin YC; Invernizzi, Alessandro; Staurenghi, Giovanni; Cheung, Chui Ming Gemmy
title: COVID-19 related retinal micro-vasculopathy – a review of current evidence COVID-19 related retinal micro-vasculopathy
date: 2021-09-26
journal: Am J Ophthalmol
DOI: 10.1016/j.ajo.2021.09.019
sha: 94c3e1f140179df2daa1dde253136af808cf3b49
doc_id: 945245
cord_uid: qezmdxil

Purpose To evaluate the occurrence of retinal micro-vasculopathy in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and developed coronavirus disease (COVID-19). Design Systematic review and meta-analysis. Methods The Pubmed and Embase databases were comprehensively searched to identify studies that reported retina vascular changes in eyes with COVID-19. Two independent reviewers selected papers and extracted data for analysis. Data of interest were extracted and analysed in RevMan Web versions 3.3. Quality of evidence was assessed using the National institute of health (NIH) quality assessment tool of case-control study. Results Thirty one studies reporting on 1373 subjects (972 COVID-19 and 401 controls) were included. Only case control studies were included in the pooled analysis. There was a significantly higher likelihood of retinal micro-vasculopathy in subjects with COVID-19 compared to controls. (odds ratio [95% confidence interval], 8.86 [2.54-27.53], p<0.01). Optical coherence tomography angiography (OCTA) reveals reduced vessel density and enlarged foveal avascular zone in subjects with COVID-19 compared to controls. Conclusions Our results suggested that COVID-19 related retinal micro-vasculopathy is a significant ocular manifestation of COVID-19 and may herald future retinal complications. These microvascular impairments might occurred antecedent to clinically visible changes and could be detected early by OCTA. These findings are significant due to the large numbers with COVID-19 and needs to be recognized by ophthalmologist as a potential long term sequelea of the disease.

The coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic in March 2020. 1 To date, there are more than 170 million confirmed COVID-19 cases globally. The virus primarily affects the respiratory system and vary from mild constitutional symptoms to pneumonia, sepsis and sometimes severe acute respiratory distress syndrome (ARDS) necessitating hospitalization and intensive care unit (ICU) admission. 2 There is increasing evidence of the virus also causing thrombo-embolic complications, with rates reported to be as high as 30%. [3] [4] [5] This thrombo-embolic sequalae is linked to thrombo-inflammation and endothelial cell injury thought to be mediated by the over production of inflammatory cytokines. 6 The eyes are not spared by COVID- 19 . In fact, anterior segment involvement has been described since early case series, manifesting as conjunctivitis. 7-10 SARS-CoV-2 RNA has been detected in infected patients' tears as well as in conjunctival tissue. 11, 12 In contrast, posterior segment manifestations are less well understood. Marinho et al first reported 12 cases of patients with mild to moderate COVID-19 infection with retinal signs including retinal hemorrhages and cotton wool spots (CWS) and optical coherence tomography (OCT) abnormalities. 13 However, several authors demonstrated how the OCT abnormalities initially reported were a misinterpretation and could be explained by variation in normal retinal vasculature on OCT b-scans. [14] [15] [16] In addition, without a comparative control group, the retinal findings such as CWS could have been non-specific and incidental. However, since the initial report by Marinho, several case-control studies have reported retinal features in patients with COVID-19 infection of various severity. [17] [18] [19] [20] [21] [22] [23] [24] [25] In addition to clinical features, several OCT angiography (OCTA) studies demonstrated reduction in vessel density (VD) in COVID patients, which corroborated with the possibility of COVID-19 related retinal micro-vasculopathy. [17] [18] [19] [20] [23] [24] [25] [26] Importantly, these perfusion deficits have been detected in asymptomatic individuals with no significant medical comorbidities who have recovered from seemingly mild COVID infections. Therefore, understanding of the prevalence and progression pattern of such perfusion deficits may have significant public health implications in the long term.

In this review, we aim to summarize the evidence and critique the evidence related to COVID-19 related retinal micro-vasculopathy and examine the potential underlying biological mechanisms.

All eligible studies were identified using a 2-level search strategy. Fist, MEDLINE and EMBASE were searched on 26/05/2021 using PubMed. The search terms used were 'retina' OR 'retinal vasculature' AND 'COVID' OR 'SARS-CoV'. Next, relevant studies were identified by two authors who reviewed the abstract of each article.

Potentially relevant studies describing retinal findings, retinal pathology and retinal imaging were retained. Each article was screened individually for reports on the prevalence of retinal signs. Studies excluded were those investigating other ocular associations with COVID infection including uveitis, ocular inflammation, and other anterior segment changes.

We summarised data separately for 1) case control studies and 2) case series. For case control studies, we planned to analyse data for the prevalence of retinal microangiopathy and quantitative changes indicative of retinal microangiopathy on OCTA. Retinal micro angiopathy was defined by the presence of retinal haemorrhages, cotton wool spots and/or vascular tortuosity on clinical examination or fundus imaging. Parafoveal vascular density (VD) and foveal avascular zone (FAZ) size were assessed as quantitative parameters on OCTA. These data were extracted from each study where available.

The number of eyes in which retinal hemorrhages or cotton wool spots in cases and controls (where available) were collated. Data regarding the prevalence of retina microangiographic signs (retinal hemorrhages and/or cotton wool spots) were pooled in the case control studies and a subject was defined to have retinal micro-vasculopathy if both or either retinal hemorrhages or cotton wool spots was detected. This data regarding retinal microvasculopathy prevalence in both the group with COVID-19 infection and non-infected controls were used to generate pooled odds ratios (ORs) and 95% confidence intervals (CIs) of presence for retinal micro-vasculopathy versus no retinal micro-vasculopathy.

In addition, data regarding the mean parafoveal VD and FAZ size (when available) on OCTA was used to generate pooled means and 95% confidence intervals (CI) of each measure respectively. Sensitivity analysis was used to confirm each difference by sequentially omitting each of the included studies and recalculating the summary difference and 95% CI. The I 2 statistic was used to determine heterogeneity across studies, such that heterogeneity was quantified irrespective of the number of studies. P value of less than 0.05 was considered to be statistically significant. Forest plots were used to summarise pooled results. Risk of bias assessment was performed on the case control studies using the National institute of health (NIH) quality assessment tool of case-control study. Pooled analysis was performed with RevMan Web versions 3.3. This review has not been registered.

We identified 227 articles from our initial search. (Figure 1 ) After reviewing the abstracts, 179 articles were excluded. The remaining 48 articles were further reviewed with full text examination. For this analysis, we included articles which described retinal signs related to micro-vasculopathy or evaluated retinal vasculature through imaging. Cases describing retinal abnormalities secondary to endophthalmitis, opportunistic infections and uveitis were not included. There were three publications by Guemes-Villahoz. 19, 26, 27 Due to overlapping recruitment period, we only included the case-control study in our analysis to avoid duplication. A follow up article by Costa et al 28 was also excluded which outlined the longitudinal outcomes of a similar cohort by Pereira et al. 29 We identified ten case-control studies (table 1), nine case series (table 2) and twelve single case reports (supplementary table 1), comprising 944 cases and 401 controls in total. In summary all case control studies were assessed to be of moderate quality when assessed by the National Institutes of Health (NIH) quality assessment tool of case-control studies. Despite the inclusion of control groups in case control studies, we observed that there was still significant heterogeneity in preexisting co-morbidities which may lead to potential selection bias. Reporting bias may affect the quality of conclusions from case series therefore we only performed pooled analysis on data from cases control studies.

Among cases-control studies and case series, 18 publications (10 case-control studies [17] [18] [19] [20] [21] [22] [23] [24] [25] 30 and 9 case series 13, 28, 29, [31] [32] [33] [34] [35] [36] ) reported on the presence or absence of retinal signs related to micro-vasculopathy. Among the 10 case-control studies, retinal signs were reported in 6, with frequency ranging from 0.01% to 20%.

The largest COVID-19 population was described by Zapata et al in a case-control study including 96 cases and 27 controls. Among the cases, a range of severity were included (24 with mild disease, 24 with moderate disease requiring hospital admission but with no acute respiratory distress and 21 with severe disease who developed ARDS and were admitted in the ICU). Age distribution was similar between cases (mean 41-44 years) and controls (mean group, no differences in OCTA parameters were found when considering the history of TE. 19 Invernizzi et al included 54 cases and 133 controls. Majority of the cases had mild infection (74%), while 26% had severe infection, but no cases requiring previous ICU were included.

Fundus examination was performed within 30 days of symptom onset. The cases were older (49.9 vs 44.2 years, p=0.01), had higher BMI (25.8 vs 24.5, p=0.03) but did not differ in other medical history compared to controls. Significantly higher frequency of retinal hemorrhages (9.25% vs 1.5%, p=0.01) and cotton wool spots (7.4% vs 0, p=0.006) were noted in COVID-19 patients compared to controls. In addition, dilated veins were more frequently observed in COVID-19 patients than in controls (27.7% vs 3.0%, p=0.0001). Semi It was noted that prevalence of hypertension and dyslipidemia was numerically higher in the COVID-19 group. Based on these results, the authors suggested that thrombotic and inflammatory phenomena could be happening in the retina of COVID-19 patients. 18 After pooling of all reported data from case-control studies which evaluated retinal signs, comprising 494 cases and 401 controls, the frequency of cotton wool spots was significantly higher in COVID-19 patients compared to subjects unexposed to the virus (1.8% vs 0.0%, p<0.01). The frequency of retinal haemorrhages was not significantly different between the two populations (1.2% vs 0.5%, p=0.25).

In addition to the reduction in VD on OCTA reported by Zapata et al, Guemes-Villahoz et al, Gonzalez-Zamora et al and Cennamo et al 18, 19, 25, 30 , three other case-control studies compared OCTA findings between COVID-19 patients to controls but did not evaluate fundus microvascular signs. 17, 20, 24 Hazar et al compared 50 COVID-19 patients with mild to moderate pneumonia with 50 controls (age 37.00 vs 35.14 years, p=0.147, respectively). Eye examination was performed one month after discharge and recovery. 20 their study cohort. 20 The results of a total of 548 subjects (318 COVID-infected versus 230 non-infected controls) were pooled for the measurement of FAZ size. The pooled mean FAZ (95% CI) was 0.08 mm 2 (0.07-0.09) larger in COVID-19 infected patients compared to noninfected controls (p<0.01). (figure 4) Sensitivity analysis performed by randomly excluding each study in a sequential manner showed a persistent significant difference between COVID-19 and control subjects with respect to the VD and FAZ size ( p < 0.05 for all). Reasons for high heterogeneity in the pooled data for VD and FAZ is likely to be due to the differences in OCTA instruments and differences in measurements methodology.

From these pooled analyses, the prevalence of retinal micro-vasculopathy is significantly associated with COVID-19 compared to controls. There is a probable association between lower VD and larger FAZ with COVID-19 compared to controls.

Nine case series reported retinal features in COVID-19 patients. Among these, the two largest series comprised 138 cases (mean age 38.5 years) 31 

Twelve published case reports evaluated fundus and/or OCT findings and reported abnormalities in 10 patients. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] Majority of these cases were symptomatic and presented with blurred vision or scotoma. In 4 cases, COVID-19 diagnosis was made as a result of systemic investigation for the ocular abnormality. 39, 42, 45, 46 There were 4 cases with retinal venous occlusion. 38, 41, 45, 46 Bilateral CWS and corresponding NFL infarct on OCT were reported in 2 cases receiving oxygen therapy. 37, 40 A further case presenting with sudden onset of scotoma was found to have CWS and evidence of paracentral acute middle maculopathy (PAMM) on OCT. 39 In the remaining 4 cases, OCT showed evidence of PAMM (3 cases), acute macular neuroretinopathy (AMN) (1 case) and GCIPL band. 43 A significant challenge in the interpretation of these findings is the potential imbalance between preexisting medical conditions in patients with COVID-19 infections and controls.

Patients tend to be older and had significantly more co-morbidities such as hypertension and diabetes. Nonetheless, the inclusion of controls has significantly improved the validity of retina micro-vasculopathy as an ocular feature of COVID-19. Among the 263 controls included in published studies, none had CWS and only 2 had micro-haemorrhages. In our pooled analysis, although it was still not possible to fully adjust for differences in patient demographics, the frequency of CWS was significantly higher in cases than in controls. The frequency of micro-haemorrhages was numerically higher but did not achieve statistically significant.

Based on the current evidence that COVID-19 may manifest as retinal micro-vasculopathy in a subgroup of infected persons, we suggest that in addition to clinical examination, OCTA, with its ability to assess the retina micro-vasculature to a high degree of accuracy, be considered the imaging modality of choice when assessing the posterior segment in this condition. However, there is currently a lack of standardized OCTA-based parameters for comparative studies. We suggest that future studies related to this condition report on two aspects of OCTA. First, perfusion characteristics such as perfused pixel area density (also known as vessel density). This metric is calculated by dividing the area of perfused pixels (often denoted as white pixels) by the area of the region of interest (ROI). Other metrics for perfusion may include perfused pixel length density (also known as skeletonized vessel density). This metric is derived by converting all vessels to a single pixel width and dividing the length of the pixels by the ROI. Non-perfusion characteristics should also be assessed.

This may be an assessment of the foveal avascular zone (FAZ) in terms of its area, circularity, or diameter. In subtle cases of micro-vasculopathy, the FAZ may remain relatively intact, hence other metrics of non-perfusion like assessing spaces between vessels may be used. These include intercapillary areas quantified by the areas of non-perfusion (black pixels) or percent area of nonperfusion, which essentially is the ration of areas of nonperfusion to area of ROI. 47, 48 Inconsistency in reported findings among COVID-19 patients may also be related to variations in the time of eye examination, severity of infection, and method of detection. 29, 34 The timing of eye examination varied considerably between published studies, with some reporting as early as 2 weeks after diagnosis of COVID-19, while others were performed at 30-88 days after diagnosis. For hospitalized patients, eye examination were carried out much later after recovery and discharge. These differences may explain in part some of the inconsistencies in the frequency of abnormal findings. The variable severity of COVID-19 is another potential confounder. Several studies suggested patients with moderate or severe disease had more retinal vasculature changes than controls or patients with mild infection.

Patients with severe COVID-19 are known to have more marked disturbance in blood parameters and are therefore at higher risk of systemic complications, including hypertension and thrombotic events. 49 These patients are also more likely to require invasive ventilation and anticoagulant therapy. The microvascular changes in the retina may be, at least in part, a result of these treatments rather than COVID-19 itself. Conversely, changes in the retinal vasculature were also seen in cases with mild symptoms who did not require hospitalization and might have been considered fully recovered in the conventional sense. 17, 21, 35 Finally, cases who were severely ill were more likely to have been examined at the bedside with handheld devices. It is possible that detection rate could have been affected due to suboptimal examination conditions. 33, 34 The mechanism through which SARS-CoV-2 may affect the retinal vasculature remains poorly understood. It is recognized that ACE-2 receptors which are involved in transmission of SARS-CoV-2 are abundant in the retina and choroid. 50 In keeping with the reduction in vessel density in in vivo studies, severely reduced microvascular density has also been reported in retina flat mount from donor eyes from COVID subjects compared to controls, which has led some investigators to propose direct effect of virus infection on endothelial cell damage. 51, 52 However, the detection of virus within the retina in post-mortem studies has been inconsistent. In addition to direct effects, hypercoagulation and vasculopathy may also lead to the observed retinal findings. [53] [54] [55] [56] In fact, fibrin microthrombi, inflammatory cells were identified in the retinal and choroidal vessels and the choriocapillaris of eyes from patients who died from COVID- 19. 52 The main limitation in the analysis is the use of only case-control studies. While cohort studies would the ideal method to determine cause or effect, in the context of the COVID-19 pandemic, it would be virtually impossible for such a prospective study to be conducted.

Sampling bias, confounders such as severity of the COVID-19 infection and preexisting conditions and patient characteristics such as age, hypertension, diabetes and hyperlipidemia may still be present despite best efforts to control them.

In summary, there are cumulating evidence suggesting possible retinal microvascular sequelae in patients infected with SARS-CoV-2. While it is important to acknowledge the potential confounders mentioned above, the scale of the potential issue warrants further investigations. At the time of writing (June 2021), there are 170 million infected individuals worldwide. Assuming retinal micro-vasculopathy develops in 10% of infected persons, this will translate into a substantial cohort. While majority of infected persons with mild symptoms may appear to have fully recovered, the longitudinal course of the retinal changes is still unknown. However, if these retinal signs persist or progress, coupled with aging and co-existence of further common systemic co-morbidities such as hypertension, hyperlipidemia and diabetes, could place these subjects at higher risk of retinal complications and visual loss. Further prospectively designed studies with large cohorts that adjust for significant confounders should be carried out to ascertain the risk of micro vasculopathy and whether these are associated with longitudinal functional deficits. 

COVID-2019) situation reports -Situation report 51. Coronavirus disease (COVID-2019) situation reports. online: World Health Organisation

Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome

The implication of ocular manifestation of COVID-19 for medical staff and patients-systematic review

Ocular manifestation, comorbidities, and detection of severe acute respiratory syndrome-coronavirus 2 from conjunctiva in coronavirus disease 2019: A systematic review and meta-analysis

2019-nCoV transmission through the ocular surface must not be ignored

Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals

Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

Retinal findings in patients with COVID-19

Seeking clarity on retinal findings in patients with COVID-19

Concerns about the interpretation of OCT and fundus findings in COVID-19 patients in recent Lancet publication

Seeking clarity on retinal findings in patients with COVID-19

Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study

Retinal Microvascular Impairment in COVID-19 Bilateral Pneumonia Assessed by Optical Coherence Tomography Angiography

Reduced macular vessel density in COVID-19 patients with and without associated thrombotic events using optical coherence tomography angiography

Macular vessel density in patients recovered from COVID 19

Retinal findings in patients with COVID-19: results from the SERPICO-19 study

Quantitative assessment of retinal changes in COVID-19 patients

Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study

Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity

Reduced retinal vessel density in COVID-19 patients and elevated D-dimer levels during the acute phase of the infection

Reduced retinal vessel density in COVID-19 patients and elevated D-dimer levels during the acute phase of the infection

Ocular findings among patients surviving COVID-19

Retinal findings in hospitalised patients with severe COVID-19

Optical Coherence Tomography Angiography Features in Post-COVID-19 Pneumonia Patients: A Pilot Study

Fundus evaluation in COVID-19 positives with non-severe disease

COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?

Retinal changes in COVID-19 hospitalized cases

Retinal involvement and ocular findings in COVID-19 pneumonia patients

Retinal microvascular signs in COVID-19

Retinal findings in patients affected by COVID 19 intubated in an intensive care unit

Purtscher-Like Retinopathy in a Patient with COVID-19. Case Rep Ophthalmol Med

Hemi-retinal vein occlusion in a young patient with COVID-19

Covid-19-associated retinopathy: a case report

Symptomatic Retinal Microangiophaty in a Patient with Coronavirus Disease 2019 (COVID-19): Single Case Report

Impending central retinal vein occlusion in a patient with coronavirus disease 2019 (COVID-19)

Retinal imaging study diagnoses in COVID-19: a case report

Paracentral acute middle maculopathy following SARS-CoV-2 infection: the D-dimer hypothesis

Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection

Central retinal vein occlusion with COVID-19 infection as the presumptive etiology

Evaluation of automatically quantified foveal avascular zone metrics for diagnosis of diabetic retinopathy using optical coherence tomography angiography

Quantifying Microvascular Abnormalities With Increasing Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and metaanalysis

Angiotensin II and its receptor subtypes in the human retina

Histopathological assessments reveal retinal vascular changes, inflammation and gliosis in patients with lethal COVID-19. medRxiv

Ocular pathology and occasionally detectable intraocular SARS-CoV-2 RNA in five fatal COVID-19 cases

Absence of severe acute respiratory syndromecoronavirus-2 RNA in ocular tissues

Severe acute respiratory Syndrome-Coronavirus-2: Can it be detected in the retina?

Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients

The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid

Dr. Teo reports consultancy fees, honorarium, travel support and speaker fees from Bayer and Novartis outside the submitted work. Dr. Cheung reports non-financial support from Bayer during the conduct of the study; grants, personal fees and non-financial support from Bayer, grants, personal fees and non-financial support from Novartis, grants from Roche, grants from GlaxoSmith Kline, non-financial support from Allergan, non-financial support from Topcon, outside the submitted work.

Abbreviations: OCT optical coherence tomography; RT-PCR reverse transcriptase polymerase chain reaction; GC-IPL ganglion cell-inner plexiform layer; CWS cotton wool spot. ARDS adult respiratory distress syndrome